Janux Therapeutics, Inc. (JANX)

NASDAQ: JANX · IEX Real-Time Price · USD
21.00
-0.84 (-3.85%)
At close: Feb 3, 2023, 4:00 PM
20.63
-0.37 (-1.76%)
After-hours: Feb 3, 2023, 4:55 PM EST
-3.85%
Market Cap 874.92M
Revenue (ttm) 7.38M
Net Income (ttm) -60.41M
Shares Out 41.66M
EPS (ttm) -1.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 63,618
Open 21.38
Previous Close 21.84
Day's Range 20.88 - 22.41
52-Week Range 9.39 - 23.64
Beta n/a
Analysts Buy
Price Target 30.26 (+44.1%)
Earnings Date Mar 17, 2023

About JANX

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programm... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 11, 2021
Employees 56
Stock Exchange NASDAQ
Ticker Symbol JANX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for JANX stock is "Buy." The 12-month stock price forecast is $30.26, which is an increase of 44.10% from the latest price.

Price Target
$30.26
(44.10% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Janux Therapeutics, Inc. (JANX) Upgraded to Strong Buy: What Does It Mean for the Stock?

Janux Therapeutics, Inc. (JANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

3 weeks ago - Zacks Investment Research

Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprieta...

1 month ago - Business Wire

Here's Why Janux Therapeutics, Inc. (JANX) Looks Ripe for Bottom Fishing

After losing some value lately, a hammer chart pattern has been formed for Janux Therapeutics, Inc. (JANX), indicating that the stock has found support. This, combined with an upward trend in earnings...

2 months ago - Zacks Investment Research

Janux Therapeutics to Present at Upcoming Investor Conferences in November

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprieta...

2 months ago - Business Wire

7 Short-Squeeze Stocks for Bold Contrarians to Consider

Throughout much of the new normal, the concept of short-squeeze stocks took off like wildfire. Essentially, this tactic centers on taking a contrarian bet against bearish traders in Wall Street's vers...

Other symbols: GHRSOFLXPOLARDVTVIA
2 months ago - InvestorPlace

Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprieta...

3 months ago - Business Wire

Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer

4 months ago - Business Wire

7 Short-Squeeze Stocks to Buy for Contrarian Investors

Short-squeeze stocks offer tremendous upside potential for people who laugh in the face of danger. Fundamentally, the concept involves betting against the pessimistic crowd with the aim of sparking a ...

4 months ago - InvestorPlace

Janux Therapeutics Appoints Brenda Van Vreeswyk as Head of Human Resources

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary tech...

4 months ago - Business Wire

Janux Therapeutics Appoints Winston Kung to Board of Directors

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary tech...

4 months ago - Business Wire

Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September

5 months ago - Business Wire

Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

6 months ago - Business Wire

Janux Therapeutics to Present at 2022 Jefferies Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to ...

8 months ago - Business Wire

Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for JANX007, a PSMA-TRACTr for Metastatic Castration-Resistant Prostate Cancer

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to ...

8 months ago - Business Wire

Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to ...

9 months ago - Business Wire

Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to ...

10 months ago - Business Wire

Janux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to ...

11 months ago - Business Wire

Janux Therapeutics to Present at Upcoming March Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to ...

1 year ago - Business Wire

Janux Therapeutics Appoints Byron Robinson, Ph.D., J.D., as Chief Strategy Officer

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to ...

1 year ago - Business Wire

Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to ...

1 year ago - Business Wire

Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to ...

1 year ago - Business Wire

Janux Therapeutics to Present Virtually at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to ...

1 year ago - Business Wire

Janux Therapeutics Appoints Ron Barrett, Ph.D., and Alana McNulty to Board of Directors

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to ...

1 year ago - Business Wire

Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to ...

1 year ago - Business Wire

Janux Therapeutics Reports Second Quarter 2021 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies based on its TRACTr platform technology, today ...

1 year ago - Business Wire